Nociception Monitoring During Epidural Analgesia

NCT ID: NCT06456177

Last Updated: 2024-07-03

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

30 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-06-30

Study Completion Date

2024-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Introduction and aim: Nociception monitors have been used to assess pain management in anesthetized patients. The investigators set out to evaluate whether Nociception Level (NOL) monitor (PMD-200 monitor with NOL technology , (Medasense Biometrics Ltd. Ramat Gan, Israel) yields reliable readings during labor, and whether the derived NOL index will be associated with Visual analogue scale (VAS) subjective level of pain before and after the onset of epidural analgesia.

Methods:

Following approval by the intuitional review board No 0056-21-CMC, thirty parturients scheduled for epidural analgesia due to labor pains will be included in this prospective study, after informed consent for participation in the study will be obtained. NOL monitoring device will be connected to the subject finger. Epidural analgesia will be performed as per institutional standards. Data of VAS and NOL index will be collected once a minute. The association between VAS and NOL before and after the onset of adequate analgesia will be evaluated.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Introduction:

Epidural analgesia is the most effective method of labor pain relief to this day. The lumbar epidural analgesia aims to induce a sensory block from T10 to L1, while at the same time facilitating the motor action of the lower limbs (L2-L5), thereby enabling the continued cooperation of the mother in the birth process.

Pain assessment is crucial for pain management and to date relies almost solely on subjective monitoring using self-assessment scales of the subject, which can be affected by personality, behavior, and psychological characteristics. Objective tools to measure pain have been developed. They rely on the changes in the balance between sympathetic and parasympathetic activity and include the heart rate variability, blood pressure, skin electrical conductivity and the vasomotor reflex and the electroencephalogram pupil. Nociception represents the integrated response to painful stimuli including the neural, hormonal and behavioral activity. Combination of multiple nociception-related parameters yielded stronger associations with the noxious stimuli compared with each parameter alone.

The PMD-200 monitor with NOL technology (Medasense Biometrics Ltd. Ramat Gan, Israel) is a novel, propriety, monitoring device based on a combination of nociception related physiological variables including heart rate, heart rate variability, photo-plethysmographic waveforms, skin conductance, and their time derivative. Based on a random forest model, the device generates the Nociception level (NOL) index, displayed as a scale from 0-100 with 0 representing no nociception and 100 representing extreme nociception. A NOL level of less than 25 arbitrary units is associated with adequate analgesia in patients under general anesthesia.

So far, the objective assessment of pain has been restricted mainly to patients who were under general anesthesia. Data in conscious patients is scant . The study design is to evaluate how nociception changes in the awake patients, and especially, how its changes following blockade of the painful stimuli. Study population parturients who will be scheduled to receive epidural analgesia for labor. This allow us to study the nociceptive level index during uterine contractions before and after the onset of epidural analgesia.

Methods:

Following approval by the intuitional review board No 0056-21-CMC, 30 parturients will be recruited and signed informed consent will be obtained.

Study protocol:

Visual analogue scale (VAS) will evaluated every 3-5 minutes and maximal NOL value within a 30 second interval will be recorded as the corresponding NOL value. Study duration will be up to 40 minutes following adequate pain relief. Total duration up to 60 minutes per parturient.

Epidural analgesia will be performed according to the protocol procedure in our institution (either sitting or lateral position with loss of resistance with either air or saline). Following insertion of an epidural catheter, a test dose of 40 mg of lidocaine will be injected to exclude spinal placement. 3 minutes later a bolus of 10 ml of 0.125% bupivacaine and 50 mcg fentanyl will be administered. VAS and NOL evaluation will proceed for up to 30 minutes after epidural analgesia commenced.

Definitions:

Baseline values (No pain relief values) are those collected before analgesia was achieved. Post epidural analgesia (Pain relief values) are those collected after the commencement of analgesia. That is after VAS dropped to 50% of highest baseline values Inadequate Epidural: Parturients who still had a VAS \> 50% of BL VAS 20 minutes after epidural injection. They were treated conventionally to control pain either by additional injection of local anesthetic, a repeated epidural or other modes of pain relief. Once diagnosed as failed epidural further data was not collected.

Outcomes:

The effect of pain relief using neuroaxial epidural analgesia in awake patients with intermittent painful stimuli (uterine contractions) the association between VAS and NOL will be evaluated.

Data analysis The measurements will be divided according to the pain status: adequate pain relief and no pain relief. The NOL and VAS distribution while with and without pain relief will be presented with Box-plots and the mean, standard deviation, median, interquartile range (IQR) and range. For each woman, the difference between the mean VAS measured while having no pain relief and the mean VAS measured while having adequate pain relief will be calculated. The difference between the VAS score with and without pain relief was compared using Wilcoxon signed rank test. P\<0.05 was considered statistically significant. The same analysis will be performed for NOL values (separately).

As each pain evaluation included both NOL and VAS values, a LOESS - Local Regression, which is a nonparametric technique that uses local weighted regression to fit a smooth curve through points in a scatter plot, will be performed. The LOESS purpose is to demonstrate the association between the VAS and the NOL.

In order to present the pain measurements along the time since the follow-up onset, a LOESS curves will be also performed. The statistical analysis and data management will be conducted using SAS 9.4 software (SAS Institute Inc., Cary, NC, USA.).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pain Relief

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Assessment of nociception in obstetric patients during epidural analgesia

Comparing nociception in obstetric patients during epidural analgesia, subjectively, by Visual analog scale and objectively by monitoring Nociception level Index

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Parturient
* Age between 20-45 years
* Present pregnancy istheir second
* Singleton births
* Under Epiduarl analgesia

Exclusion Criteria

* Age younger than 20 years or older than 45 years
* First pregnancy
* Multiple birth
Minimum Eligible Age

20 Years

Maximum Eligible Age

45 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Carmel Medical Center

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Michael Grach

Director of outpatient pain medicine clinic

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Dana Koos, Dr. MD

Role: STUDY_CHAIR

[email protected]

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Carmel Medical Center

Haifa, , Israel

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Israel

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

0056-21-CMC

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.